News >

Incorporating Neoadjuvant and Adjuvant Data in Early-Stage HER2+ Breast Cancer

Caroline Seymour
Published: Wednesday, Jun 26, 2019

Yee Chung Cheng, MD

Yee Chung Cheng, MD

Given the number of positive neoadjuvant and adjuvant trials that have surfaced in early-stage HER2-positive breast cancer in recent years, it can be difficult to properly integrate these agents into practice. However, with careful consideration of the data, physicians can optimize available anti-HER2 therapy for their patients, said Yee Chung Cheng, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x